Survey on the use of methotrexate by pediatric rheumatologists in Canada

Journal of Rheumatology

Volumn 34, Issue 4, 2007, Pages 818-822

  Chédeville, Gaëlle ^a   Scuccimarri, Rosie ^a   Duffy, Ciarán M ^a  

^a MONTREAL CHILDREN S HOSPITAL   (Canada)

Author keywords

Guidelines; Methotrexate; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; CREATININE; FOLIC ACID; METHOTREXATE;

ABNORMAL LABORATORY RESULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CELL COUNT; BLOOD DYSCRASIA; CANADA; DRUG MONITORING; DRUG USE; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; HEALTH SURVEY; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; LIVER CIRRHOSIS; LIVER TOXICITY; MEDICAL PRACTICE; MEDICAL SOCIETY; NAUSEA; PEDIATRICIAN; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RHEUMATIC DISEASE; RHEUMATOLOGY; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING;

ANTIRHEUMATIC AGENTS; CANADA; DRUG TOXICITY; HEALTH CARE SURVEYS; HUMANS; METHOTREXATE; PEDIATRICS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; RHEUMATOLOGY;

EID: 34247350018     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Giannini E, Brewer E, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-USSR double blind, placebo controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med 1992;326:1043-9.
2. Cron RQ, Sharma S, Sherry DD. Current treatment by United States and Canadian pediatric rheumatologists. J Rheumatol 1999;26:2036-8.
3. Laxer R. Disease-modifying antirheumatic drugs. Methotrexate. In: Cassidy J, Petty R, Laxer R, Lindsley C, editors. Textbook of pediatric rheumatology. 5th ed. Philadelphia: Saunders; 2005:88-96.
4. Kremer J, Alarcon G, Lightfoot R, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994;373:316-28.
5. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 2002;46:328-46.
6. Yazici Y, Erkan D, Paget S. Monitoring methotrexate hepatic toxicity in rheumatoid arthritis: Is it time to update the guidelines? J Rheumatol 2002;29:1586-9.
7. Yazici Y, Erkan D, Paget S. Monitoring by rheumatologists for methotrexate, etanercept, infliximab, and anakinra-associated adverse effects. Arthritis Rheum 2003;48:2769-72.
8. Cartwright V, Michaud K, Choi H, Wolfe F. Methotrexate laboratory testing and risk of serious illness: analyses in 20,000 patients. Arthritis Rheum 2003;48:S428-S429.
9. Ortiz-Alvarez O, Morishita K, Avery G, et al. Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol 2004;31:2501-6.
10. Yazici Y, Sokka T, Kautiainen H, Swearingen C, Kulman I, Pincus T. Long-term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely due to laboratory abnormalities. Ann Rheum Dis 2005;64:207-11.
11. Kent P, Luthra H, Michet C. Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis. J Rheumatol 2004;31:1727-31.
12. Graham LD, Myones BL, Rivas-Chacon RF, Pachman LM. Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis. J Pediatr 1992;120:468-73.
13. Lahdenne P, Rapola J, Ylijoki H, Haapasaari J. Hepatotoxicity in patients with juvenile idiopathic arthritis receiving longterm methotrexate therapy. J Rheumatol 2002;29:2442-5.
14. Ramanan A, Whitworth P, Baildam E. Use of methotrexate in juvenile idiopathic arthritis. Arch Dis Child 2003;88:197-200.